Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube

ISPOR 11th Annual International Meeting
May 20-24, 2006  Marriott Philadelphia, Philadelphia, PA
 

CONTRIBUTED POSTER PRESENTATIONS SESSION II


 

Cancer

   
PCN1 ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG CANCER ADJUVANT TREATMENTS IN PRACTICE USING INSTRUMENTAL VARIABLE METHODS
Brooks JM1, Chrischilles EA2, Chen-Hardee S1, Cho E1, Scott SD3
1University of Iowa, Iowa City, IA, USA, 2Univerisity of Iowa, Iowa City, IA, USA, 3University of Newcastle, Newcastle, Australia
PCN2 Withdrawn
   
PCN3 AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR DELAYED NAUSEA AND VOMITING USING ELECTRONIC MEDICAL RECORDS
Forsyth M1, Conner T1, Curtis V1, Johnsrud M2
1US Oncology, Houston, TX, USA, 2University of Texas at Austin, Austin, TX, USA
   
PCN4 RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF ENDOMETRIAL CANCER
Wang C, He J, Griffin B, Mahoney A, Burleigh E
Solucient, Berkerley Heights, NJ, USA
   
PCN5 QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH BREAST CANCER AND ITS ECONOMIC CONSEQUENCES IN MEXICO
Contreras-Hernandez I1, Mould J1, Pico-Guzman J2, Ayala-Hernandez JR1, Garduńo-Espinosa J1
1Social Security Mexican Institute, Mexico City, Mexico, 2Life Sciences Consulting, Madrid, Spain
   
PCN6 HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH CANCER AND PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD)
Smith J1, He J1, Mahoney A1, Noone P2, Watson S3, Mody S3, Mckenzie RS3
1Solucient, LLC, Berkeley Heights, NJ, USA, 2Ortho Biotech Products, LP, Bridgewater, NJ, USA, 3Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
   
PCN7 WITHDRAWN
   
PCN8 COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN
Ikeda S1, Sakamaki H2, Yajima S2, Ikegami N2
1International University of Health and Welfare, Otawara-shi, Tochigi, Japan, 2Keio University, Shinjuku-ku, Tokyo, Japan
   
PCN9 ECONOMIC EVALUATION OF ANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Mody RR1, Miller LA2, Higa G2, Scott V2, Madhavan SS2, Abraham J2
1TAP Pharmaceutical Products Inc, Lake Forest, IL, USA, 2West Virginia University, Morgantown, WV, USA
   
PCN10 COST-EFFECTIVENESS OF GEMCITABINE-PACLITAXEL COMBINATION IN THE TREATMENT OF ADVANCED BREAST CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY
Davey P1, Arora BK2, Le Reun C1, Rajan N2, Liepa AM3, Pavlakis N4
1M-TAG Pty Ltd - A unit of IMS Health, Sydney, NSW, Australia, 2Eli Lilly Australia Pty, Ltd, West Ryde, NSW, Australia, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Royal North Shore Hospital, St. Leonards, NSW, Australia
   
PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER
Kerrigan M1, Ramsey S2, Penson D3, Blough DK1, Garrison L1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3University of Southern California / Norris Cancer Center, Los Angeles, CA, USA
   
PCN12 COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL) RECEIVING CHOP
Lyman GH1, Cosler LE2
1University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, 2Albany College of Pharmacy, Albany, NY, USA
   
PCN13 COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY
Annemans L1, Strens D1, Lox E2, Petit C2, Malonne H2
1HEDM-IMS Health, Brussels, Belgium, 2Merck Sharp & Dohme bv, Brussels, Belgium
   
PCN14 COST - EFFECTIVENESS OF TAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER
Kawatkar AA, Hay JW
University of Southern California, Los Angeles, CA, USA
   
PCN15 THE ANNUAL HEALTH INSURANCE COST OF COLORECTAL CANCER TREATMENT IN HUNGARY: A COST OF ILLNESS STUDY
Boncz I1, Sebestyén A1, Palásti J1, Betlehem J2
1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2University of Pécs, Pécs, Hungary
   
PCN16 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS: A MEDICARE PERSPECTIVE
Pelletier EM1, Dembek CJ1, Gazelle GS2
1Boston Scientific Corporation, Natick, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA
   
PCN17 EVALUATING THE COST OF CARE FOR EARLY AND LATE STAGE OROPHARYNGEAL CANCER IN THE CALIFORNIA MEDICAID POPULATION
Epstein JD1, Knight TK1, Epstein JB2, Bride M3, Nichol MB1
1University of Southern California, Los Angeles, CA, USA, 2University of Illinois at Chicago, Chicago, IL, USA, 3Zila, Inc, Phoenix, AZ, USA
   
PCN18 CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY
Nuyts G1, Janagap C1, Zilberberg M2, Piech CT2
1Johnson and Johnson, Raritan, NJ, USA, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
   
PCN19 COLONOSCOPY AND FLEXIBLE SIGMOIDOSCOPY: A MICROCOSTING STUDY EVALUATING DIAGNOSTIC PROCEDURAL COSTS IN AN OUTPATIENT ENDOSCOPY CLINIC
Sambrook JC1, Chui W1, Wang H1, Levy AR1, Enns RA2
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2St. Paul's Hospital, Vancouver, BC, Canada
   
PCN20 COSTS OF THE DIFFERENT TREATMENTS FOR PATIENTS WITH BREAST CANCER IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS).
Salinas-Escudero G1, Mould J1, Duran-Arenas L1, Martinez-Valverde S2, Garduńo-Espinosa J1
1Social Security Mexican Institute, Mexico City, Mexico, 2Social Security Research Unit, Mexico City, Mexico
   
PCN21 4D LOCALIZATION SYSTEM WITH TRANSPONDERS FOR CONTINUOUS TARGET LOCALIZATION FOR SET-UP AND TRACKING DURING RADIATION THERAPY: EARLY HEALTH TECHNOLOGY ASSESSMENT
Williams E1, Papatheofanis FJ2
1AEQUITAS, San Diego, CA, USA, 2UCSD, San Diego, CA, USA
   
PCN22 THE EFFECT OF EFFICIENCY OF ACCESS TO CARE
Younis M1
1Tulane, New Orleans, LA, USA
 
PCN23 THE EFFECT OF ORGANIZED MAMMOGRAPHY SCREENING ON THE NUMBER OF BREAST SURGERIES
Boncz I1, Sebestyén A2, Budai A3, Ember I4
1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2National Health Insurance Fund Administration (OEP), Pécs, Hungary, 3National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 4University of Pécs, Pécs, Hungary
   
PCN24 DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT- AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL
Brentani A1, Diz MDPE2, Maistro S1 Snitcovsky I2, Federico M1
1Faculdade de Medicina da universidade de Sao Paulo, Sao Paulo, Brazil, 2Hospital das Clínicas da FMUSP, Săo Paulo, Brazil, 3Faculdade de Medicina Da Universidade de Săo Paulo, Sao Pulo, Brazil
   
PCN25 REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A NATIONWIDE SAMPLE OF PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY: RESULTS FROM A LARGE RETROSPECTIVE OBSERVATIONAL STUDY
McLaughlin T1, Mody S2, Mckenzie RS2
1Stanford University Medical Center, Stanford, CA, USA, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
   
PCN26 INTER-RATER AGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT VERSUS CLINICIAN ASSESSMENT
Rae CS1, Furlong W1, Gelber R2, Barr RD1
1McMaster University, Hamilton, ON, Canada, 2Harvard University, Boston, MA, USA
   
PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS
Furlong W1, McCarter H2, Whitton AC2, Feeny D3, DePauw S1, Willan AR4, Barr RD1
1McMaster University, Hamilton, ON, Canada, 2Juravinski Cancer Centre, Hamilton, ON, Canada, 3Institute of Health Economics, Edmonton, AB, Canada, 4Hospital for Sick Children, Toronto, ON, Canada
   
PCN28 REVIEW OF ECONOMIC APPRAISALS OF CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER
Hornberger J1, Robertus K1, Bhattacharyya SK2, Deeter R2
1Acumen, LLC, Burlingame, CA, USA, 2Amgen Inc, Thousand Oaks, CA, USA
   
PCN29 GAPS IN THE ECONOMIC EVALUATION OF PROSTATE CANCER
Komatsuzaki Y1, Atzinger C1, Lee WC2, Pashos CL2
1Abt Associates Inc, Bethesda, MD, USA, 2Abt Associates Inc, Lexington, MA, USA
   
PCN30 WITHDRAWN
   
PCN31 A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES
Baser O
Thomson-Medstat, Ann Arbor, MI, USA
   
PCN32 MODELING AND ESTIMATING PREFERENCES OVER TREATMENTS FOR BREAST CANCER: APPLIED CONJOINT ANALYSIS WITH PHYSICIANS IN EUROPE AND UNITED STATES
Walzer S1, Memran M2, Morlotti L1
1Analytica International, Loerrach, Germany, 2Analytica International, New York, NY, USA
 
PCN33 MAPPING FACT-P AND EORTC QLQ-C30 TO THE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS
Wu E1, Mulani P2, Farrell MH1, Sleep D2
1Analysis Group, Inc, Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA
   
PCN34 VALIDATION OF AN INTERNET-BASED PATIENT HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE: DATA FROM CAPSURE
Broering JM1, Lessard SC1, Marr PL1, Elkin EP1, Lewis KR2, Olesek G2, Carroll PR1, DuChane J3
1University of California, San Francisco, San Francisco, CA, USA, 2Secure Outcomes Corporation, Santa Clara, CA, USA, 3TAP Pharmaceutical Products, Inc, Lake Forest, IL, USA
   
PCN35 DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC, NEUROENDOCRINE TUMOR QUESTIONNAIRE (QOL-NET), TO MEASURE PATIENTS' PERCEPTION OF THE EFFECTS OF DISEASE ON THEIR QUALITY OF LIFE (QOL)
Vinik EJ, Ford-Molvik SL, Vinik AI
Eastern Virginia Medical School, Norfolk, VA, USA
   
PCN36 DEVELOPING HEALTH STATE DESCRIPTIONS FOR METASTATIC COLORECTAL CANCER: QUALITATIVE STUDY
Lloyd A1, van Hanswijck de Jonge P1, Doyle S1, Walker M2, Cohen C2
1United Biosource Corporation, London, UK, 2Roche Products Ltd, Welwyn Garden City, Herts, UK
   
PCN37 ESTIMATION OF A SET OF PATIENT-BASED UTILITY WEIGHTS FOR THE FACT-G
Dobrez D1, Pickard AS2, Cella D3, Lai JS4, Nickolov A5
1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, UIC, Chicago, IL, USA, 3Evanston Northwestern Healthcare, Chicago, IL, USA, 4Evanston Northwestern Healthcare, Evanston, IL, USA, 5Mallinckrodt/Tyco Healthcare, St Louis, MO, USA
   
PCN38 PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP
Baser O
Thomson Medstat, Ann Arbor, MI, USA
   
PCN39 A SYSTEMATIC REVIEW OF THE UCLA PROSTATE CANCER INDEX'S MEASUREMENT PROPERTIES
Epstein JD1, Gwadry-Sridhar F2
1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, and London Health Sciences Centre, London, ON, Canada
   
PCN40 THE IMPACT OF HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER ON HEALTH-RELATED QUALITY OF LIFE: A REVIEW OF VALIDATED INSTRUMENTS CURRENTLY AVAILABLE
Rofail D1, Abetz L2, Jenkins D3, Lindsay L3, De Vuyst H3
1Mapi Values Limited, Macclesfield, Cheshire, UK, 2Mapi Values Limited, Bollington, Cheshire, UK, 3GSK Biologicals, Rixensart, Belgium
   
PCN41 EQ-5D IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ASSESSMENT OF VALIDITY AND RESPONSIVENESS.
Sundaram M1, Kutikova L2, Enas NH2, Lu H2, Liepa AM2
1West Virginia University School of Pharmacy, Morgantown, WV, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
   
PCN42 PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS: DATA FROM CAPSURETM
Sadetsky N1, Elkin EP2, Carroll PR2
1UCSF, San Francisco, CA, USA, 2University of California, San Francisco, San Francisco, CA, USA
   
PCN43 A SYSTEMATIC REVIEW OF THE EORTC QLQ-BR23: DESCRIPTIVE HEALTH RELATED QUALITY OF LIFE INSTRUMENT USED IN BREAST CANCER
Kawatkar AA1, Gwadry-Sridhar F2
1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, and London Health Sciences Centre, London, ON, Canada
   
PCN44 IMPROVEMENT IN SENSORY PAIN RATING AFTER PALLIATIVE RADIONUCLIDE THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER
Papatheofanis FJ1, Marangos P2
1UCSD, San Diego, CA, USA, 2Aequitas, San Diego, CA, USA
   
PCN45 EFFECT OF AGE ON PREFERENCES FOR HEALTH OUTCOMES IN PROSTATE CANCER
Krahn MD1, Bremner K1, Tomlinson G2, Alibhai S3, Laporte A4, Naglie G5
1University Health Network, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Unviersity Health Network, Toronto, ON, Canada, 4Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5Unversity Health Network, Toronto, ON, Canada
   
PCN46 ONLINE REPORTING OF TOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY
Basch E, Barz A, Kris M, Culkin A, Schrag D
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
   

Contributed Posters Session I

 


11th Annual Meeting Main Page
 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.